Exact Sciences (EXAS)
(Delayed Data from NSDQ)
$56.36 USD
-2.46 (-4.18%)
Updated Aug 14, 2024 03:59 PM ET
After-Market: $56.56 +0.20 (0.35%) 7:58 PM ET
2-Buy of 5 2
D Value A Growth F Momentum B VGM
Brokerage Reports
0 items in cart
Exact Sciences Corporation [EXAS]
Reports for Purchase
Showing records 181 - 200 ( 369 total )
Company: Exact Sciences Corporation
Industry: Medical - Biomedical and Genetics
CMS Reimbursement Likely at $502 -Significant Win; Buy
Provider: Roth Capital Partners, Inc.
Analyst: LEWIS C
Company: Exact Sciences Corporation
Industry: Medical - Biomedical and Genetics
Receives Positive Recommendation for a National Coverage Decision from CMS
Provider: The Benchmark Company
Analyst: WALD J
Company: Exact Sciences Corporation
Industry: Medical - Biomedical and Genetics
Company: Exact Sciences Corporation
Industry: Medical - Biomedical and Genetics
MID-DAY SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Exact Sciences Corporation
Industry: Medical - Biomedical and Genetics
Wins FDA Approval; CMS Preliminary National Coverage Decision Process also Begins
Provider: The Benchmark Company
Analyst: WALD J
Company: Exact Sciences Corporation
Industry: Medical - Biomedical and Genetics
Cologuard Wins FDA Approval, CMS Issues Proposed NCD; Reiterate Buy
Provider: Roth Capital Partners, Inc.
Analyst: LEWIS C
Company: Exact Sciences Corporation
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences - Upcoming Events for the Week of August 4
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Exact Sciences Corporation
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Exact Sciences Corporation
Industry: Medical - Biomedical and Genetics
Upcoming Catalysts and Commercial Launch in Sight; Buy
Provider: Roth Capital Partners, Inc.
Analyst: LEWIS C
Company: Exact Sciences Corporation
Industry: Medical - Biomedical and Genetics
Exact Sciences Second Quarter, Rearing to Go on FDA Approval
Provider: The Benchmark Company
Analyst: WALD J
Company: Exact Sciences Corporation
Industry: Medical - Biomedical and Genetics
2Q14 Recap - Inspection Complete, Teeing Up Near-Term Approval.
Provider: WEDBUSH SECURITIES INC.
Analyst: KHURSHID Z
Company: Exact Sciences Corporation
Industry: Medical - Biomedical and Genetics
2Q14 Preview - Expecting Clarity on Facility Inspection Timing - Payor Discussions Intrigue Us - Maintain N
Provider: WEDBUSH SECURITIES INC.
Analyst: KHURSHID Z
Company: Exact Sciences Corporation
Industry: Medical - Biomedical and Genetics
2Q 2014: Quarterly Medical Technology Trading & Acquisition Valuation UpdateThis report contains brief updates on the following: ALGN, BABY, ETRM, EXAS, ICUI, LMAT, MASI, NSPH, TEAR, TRIB, UPI, VOLC. These companies are covered in more detail in separate Daily Notes and/or Company Reports.
Provider: Roth Capital Partners, Inc.
Analyst: LEWIS C
Company: Exact Sciences Corporation
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences - Upcoming Events for the Week of July 14
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Exact Sciences Corporation
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences - Upcoming Events for the Week of July 14
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Exact Sciences Corporation
Industry: Medical - Biomedical and Genetics
Company: Exact Sciences Corporation
Industry: Medical - Biomedical and Genetics
LIFE SCIENCES AND HEALTH CARE
Provider: WEDBUSH SECURITIES INC.
Company: Exact Sciences Corporation
Industry: Medical - Biomedical and Genetics
Downgrading to NEUTRAL from OUTPERFORM - Taking a Breather After Stock Reaches PT and While We Wait for Approval and Preliminary Coverage Decision
Provider: WEDBUSH SECURITIES INC.
Analyst: KHURSHID Z
Company: Exact Sciences Corporation
Industry: Medical - Biomedical and Genetics
Company: Exact Sciences Corporation
Industry: Medical - Biomedical and Genetics
Downgrading to NEUTRAL from OUTPERFORM - Taking a Breather After Stock Reaches PT and While We Wait for Approval and Preliminary Coverage Decisio
Provider: WEDBUSH SECURITIES INC.
Analyst: KHURSHID Z